Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs
06 déc. 2021 07h30 HE
|
Mydecine Innovations Group Inc.
Dr. Saeid Babaei Appointed Independent Board Member as Mydecine Moves Closer to NASDAQ Listing in Q1 2022 DENVER, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC:...
Mydecine Reports Third Quarter 2021 Financial Results and Provides Business Update
16 nov. 2021 07h30 HE
|
Mydecine Innovations Group Inc.
--To Launch Phase 2/3 Smoking Cessation Clinical Trial with Johns Hopkins University (JHU) Signed 5-Year Research Agreement with JHU to Further Mydecine’s Research of Multiple Molecules for a Variety...
Mydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’ Veterans & Families Forum on November 10, 2021
10 nov. 2021 07h30 HE
|
Mydecine Innovations Group Inc.
DENVER, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to...
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Leader in Emerging Psychedelic-Assisted Psychotherapy Industry
04 nov. 2021 08h30 HE
|
Mydecine Innovations Group Inc.
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) announces the availability of a broadcast titled, “Breaking the Habit:...
Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion Technology to Traditional Medicine Ingredients
03 nov. 2021 07h30 HE
|
Mydecine Innovations Group Inc.
DENVER, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to...
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Part of Psychedelic Medicine Research Renaissance
02 nov. 2021 08h30 HE
|
Mydecine Innovations Group Inc.
NEW YORK, Nov. 02, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) today announces its placement in an editorial published by...
Mydecine to Participate in Wonderland: Miami on November 8-9, 2021
29 oct. 2021 07h30 HE
|
Mydecine Innovations Group Inc.
DENVER, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biotechnology and digital technology company focused on the...
Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties of Psilocin
27 oct. 2021 07h30 HE
|
Mydecine Innovations Group Inc.
Further strengthens the Company’s drug development pipeline of tryptamines by introducing novel psilocin analogues containing enhancements in safety and efficacy tailored for medical use DENVER, Oct....
Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead by Dr. Matthew Johnson
05 oct. 2021 07h30 HE
|
Mydecine Innovations Group Inc.
DENVER, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biopharmaceutical company focused on the treatment of...
Mydecine Completes Spin-Out of U.S. Cannabis Assets
01 oct. 2021 07h30 HE
|
Mydecine Innovations Group Inc.
DENVER, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biopharmaceutical company focused on the treatment of...